|
Thursday 22nd June 2023 |
Text too small? |
Cannasouth Limited, (NZX: CBD ), is pleased to announce that Eqalis Pharmaceuticals Ltd’s’ first cannabis-based ingredient has been successfully verified by the Medicinal Cannabis Agency (Agency) as meeting the New Zealand minimum quality standard. This achievement allows for local and export ingredient sales and is key to verifying future medicinal cannabis products.
On 1 June 2023, Cannasouth merged with Eqalis Group, enabling Cannasouth to operate end-to-end with GMP approval for producing dried cannabis flower, as well as manufacturing cannabis-based ingredients and medicinal cannabis products such as oral solutions.
CEO Mark Lucas says, “This new product verification is part of the momentum we expected from our merger with Eqalis, leading towards revenue generation. It follows Cannasouth's first commercial export shipment of high-quality dried cannabis flower to Australia this month, and we anticipate confirmation from the Agency soon regarding the verification of Eqalis’ two new oral solution products.”
“Meanwhile, we are progressing flower product applications for the New Zealand market and development for the first of our next-generation medicinal cannabis products. Cannasouth’s product development pipeline is based on new drug technologies designed to provide a platform for numerous therapeutic products offering potential for licence opportunities and royalty revenue streams.”
-ENDS-
No comments yet
STU - Steel & Tube - Trading Update and Facility Extension
ARG - Argosy FY27 Interim Result
RGI - Reefton Resource Update and PFS
NPH - 2026 Full Year Results
Devon Funds Morning Note - 18 November 2026
IFT - Interim results for the period ended 30 September 2026
November 18th Morning Report
IPL - Interim Results HY27
SEK - Seeka Announces Launch of 2026 Grower Loyalty Share Scheme
SAN - Sanford delivers a record profit for FY26